Unicycive Therapeutics develops disease-modifying therapies for kidney diseases, utilizing proprietary nanoparticle technology in its investigational drug Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia. The company addresses the unmet medical needs of patients suffering from acute kidney injury and related conditions.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with kidney disease, particularly those with acute kidney injury or hyperphosphatemia, face significant challenges due to limited treatment options and the need for effective therapies to manage phosphate levels. Existing treatments may have limitations in terms of efficacy, tolerability, or ease of administration, creating an unmet need for improved therapeutic interventions.
Solution
Unicycive Therapeutics is developing disease-modifying therapies for kidney diseases, with a focus on addressing hyperphosphatemia and acute kidney injury. Their investigational drug, Oxylanthanum Carbonate (OLC), utilizes a proprietary nanoparticle technology to manage phosphate levels in patients with hyperphosphatemia. OLC aims to provide a more convenient and effective treatment option compared to existing therapies. Additionally, Unicycive is developing UNI-494, targeting mitochondrial dysfunction, which is believed to play a critical role in acute kidney injury.
Target Audience
The primary target audience includes patients suffering from kidney diseases, specifically hyperphosphatemia and acute kidney injury, as well as healthcare providers specializing in nephrology.
Features
- Oxylanthanum Carbonate (OLC): Utilizes proprietary nanoparticle technology for phosphate management.
- OLC is designed to be a smaller tablet that is swallowed whole with water.
- UNI-494: Targets mitochondrial dysfunction in acute kidney injury.